Endocrine - Parathyroid disease Flashcards

1
Q

Physiological effects of PTH

Source of PTH

A

↑Ca ↓PO4 ↑ALP

  1. Increase Ca resorption from bone via osteoblasts and osteoclasts
  2. Increase reabsorption of Ca from DCT in kidneys, Decrease Phosphate reabsorption
  3. Increase intestinal uptake of Ca via formation of 1,25-dihydroxyvitamin D

Source: parathyroid chief cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Physiological effects of Vitamin D

Sources of Vit D

Processing

A

↑Ca ↑PO4 ↑ALP

  1. Increase Ca uptake in intestine by increase Calcium Binding Protein
  2. Increase Calcium resorption from bone in high dose
  3. Increase Phosphate uptake in intestine

Processing: vitamin D3 or D2
→ 25-hydroxylation in liver → calcidiol (25-(OH)-D3)
→ 1-hydroxylation in kidney → calcitriol (1,25-(OH)2-D3)

Source:

→ Dietary: D3 from animal, D2 from plants
→ Sunlight: D3

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Physiological effects of Calcitonin

Source of Calcitonin

A

↓Ca ↓PO4

(physiologically negligible to Ca homeostasis as thyroidectomy does NOT affect serum Ca)

  1. Decrease Osteoclast-mediated bone resorption
  2. Decrease reabsorption of Ca from DCT in Kidney, Increase Phosphate excretion

Source: thyroid parafollicular C cells

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

List all physiological factors that modulate serum Ca level

A

PTH

Calcitonin

Vitamin D

Albumin: Alb-bound Ca amounts to 40% of plasma Ca

Phosphate level (affect ionic calcium balance, can precipitate Ca out of serum)

Serum pH level (affect ionic calcium level, H+ ions compete with Ca2+ ions for binding sites on albumin)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Corrected Calcium

  • Indications
  • Formula
A

Indication: Any condition with hypoalbuminaemia (most Ca bind to albumin, remainder bind to globulin)

Total Calcium may be low but Ionized Calcium is normal

  • Nephrotic syndrome
  • Liver cirrhosis
  • Malnutrition
  • Protein-losing enteropathy
  • Acute or chronic inflammation (negative phase reactant)
  • Absorptive problem: e.g. IBS, Bowel cancer…etc

Formula = Total Ca (mmol/L) + [0.02 x (40 - albumin in g/L)]

Albumin-corrected Ca =
For each ↓1g/L in Alb below 40g/L, Ca should be adjusted ↑0.02mmol/L (provided that Alb is between 20-51).

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Role of albumin in blood

A
  1. regulation of colloid osmotic pressure or protein concentration within the blood plasma
  2. transport of free fatty acids and other molecules to the liver (unconjugated bilirubin, metals, ions) for storage or utilization
  3. binding of drugs and alteration of pharmacokinetics (half-life, biological activity levels, metabolism)
  4. buffering plasma pH
  5. scavenging reactive oxygen species to avoid inflammation and associated damage
  6. functioning as a reservoir of nitric oxide for the regulation of blood pressure
  7. prevention of coagulation and platelet aggregation in an action similar to the commonly used anticoagulant heparin
  8. inhibits inflammatory mediators such as TNF-α and complement 5a (C5a) to reduce the overall inflammatory response
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Causes of Hypercalcemia

A
  1. Hyperparathyroidism (Primary or tertiary)
  2. Hypercalcemia of Malignancy
  3. Excessive vitamin D or Calcium (Vit. D intoxication, Milk alkali syndrome)
  4. Granulomatous disease - Increase sensitivity to Vitamin D (e.g. Tuberculosis, Sarcoidosis)
  5. Hypocalciuric Hypercalcemia (Thiazide diuretics, Familial mutation of Calcium sensing receptor CaSR)
  6. Adrenal insufficiency
  7. Hyperthyroidism
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pathophysiology of adrenal insufficiency causing Hypercalcemia

A

Hypovolaemia > Reduced GFR > Reduced calcium filtration > Increase Calcium renal reabsorption

Increase 1-alpha- hydroxylase activity > Increase intestinal absorption of Calcium

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Outline the flowchart for approaching hypercalcaemia

A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

S/S hypercalacaemia

A

Mostly asymptomatic

□ Non-specific: fatigue, depression, drowsiness, malaise

□ Specific: usually clinically a/w dehydration
→ Stones: nephrocalcinosis, renal stones (if long-standing)
→ Bones: bone pain, osteoporosis (if hyperPTH)
→ Moans: constipation, anorexia, abdominal pain, PUD, pancreatitis
→ Thrones: polyuria, dehydration, polydipsia
→ Psychic overtones: confusion, depression, anxiety, hallucination

□ Others: band keratopathy, short QTc, distal RTA

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Outline mild, moderate and severe hypercalcaemia levels

A

Mild:

Serum Ca < 3 mmol/L

Moderate:

Serum Ca 3.0 - 3.5 mmol/L

Severe:

Serum Ca > 3.5 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Management of mild symptomatic hypercalcaemia

A
  1. Avoid aggravating factors
  2. Maintain hydration
  3. Avoid high calcium diet (>1000mg/day)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Management of moderate/ severe hypercalcaemia

A
  1. Rapid control of Ca level
  2. Early Dx of underlying cause

Medical options:

  • Fluid replacement with Saline +/- Loop diuretics
  • IV bisphosphonate (Zoledronic acid or Pamidronate)
  • Calcitonin (subcutaneous)
  • Glucocorticoids (Prednisolone)
  • Monoclonal antibodies against RANKL
  • Dialysis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Fluid replacement for HyperCa

MoA, Monitoring

A

MoA:

  • Infuse normal saline > inhibition of sodium reabsorption in PCT and Loop of Henle > Excretion of Calcium

Monitoring:

  • Infusion rate depends on age, comorbid conditions (HF, CKD…etc)
  • Monitor electrolytes and fluid balance
  • Add Loop diuretics (Frusemide) if develop edema after rehydration
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

IV bisphosphonate for hyperCa

MoA

Indication

Time course

S/EE

A

MoA:

Inorganic pyrophosphate analog absored to surface of bone hydroxyapatite > Interfere with osteoclast-mediated bone resorption > Decrease Ca release from bone

Indication: Moderate to severe HyperCa

Time course: 1-2 days to take effect, 2-4 days for maximum effect

S/E: Osteonecrosis of jaw, Atypical fracture, Flu-like symptoms, renal impairment

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Calcitonin for HyperCa

MoA

Time course

S/E

A

MoA: Increase renal Ca excretion and decrease bone resorption

Time course: Rapid onset, give subcutaneously every 12 hours (Salmon Calcitonin)

S/E: Nausea, Hypersensitivity reaction, Tachyphylaxis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

Glucocorticoids for HyperCa

MoA

Indication

A

MoA: Decrease Calcitriol production by activated mononuclear cells

Indications:

  • Excessive ingestion or admin. of Vitamin D
  • Endogenous overproduction of calcitriol - Granulomatous diseases, lymphoma…etc
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Monoclonal Ab against RANKL for HyperCA

MoA

Indication

Precaution

A

MoA:

Block the action of RANK Ligand released by Osteoblasts that increase formation, activity and survival of osteoclasts

Decrease bone resorption and Ca release

Indication:

Refractory Tx to IV bisphosphonate

Contraindicated for IV bisphosphonate due to renal failure (Denosumab not excreted through kidneys)

Persistent HyperCa due to malignancy

Precaution: Vitamin D depletion before admin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Dialysis for HyperCa

Indication

A

Very severe HyperCa (Serum Ca > 4.5 mmol/L)

Refractory severe hyperCa complicated by renal failure (renders other therapy ineffective/ contraindicated)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Most common cause of hypercalcaemia

Epidemiology

Subtypes

A

Primary hyperparathyroidism

Epidemiology:

  • 6th-7th decade
  • F:M - 2-3:1
  • 1-2/1000

Types:

  • Solitary parathyroid adenoma (85%)
  • Parathyroid hyperplasia (10-15%)
  • Double adenoma (1-2%)
  • Parathyroid carcinoma (1%)
21
Q

Symptoms of severe hyperCa

A

Constitutional: Weakness, tiredness, anorexia

GIT: Nausea, vomiting, constipation

Nephrogenic DI: Thirst, dry mouth, polyuria

Neural: Mental confusion and drowsiness

22
Q

Complications of severe hyperCa

A

Renal:

Renal stone, nephrocalcinosis, hypertension, renal failure

Bone:

Osteoporosis, bone pain, fracture, Parathyroid bone disease

Gastrointestinal:

Epigastric pain, dyspepsia

MSS:

Calcification of cartilage, joint pain

Endocrine: Multiple endocrine neoplasia (MEN1, MEN2)

23
Q

Pharmacological effect of PTH on bones

A

Intermitted low dose (Teriparatide) - Anabolic action with increase BMD (indicated Osteoporosis)

Continuous high dose - Bone resorption (esp. cortical bone more than trabecular bone)

24
Q

Features of parathyroid bone disease

A

Cystic osteitis fibrosa and osteopenia

Bone pain, subperiosteal resorption (esp. at phalanges)

Bone deformity: Bone cysts (esp. at central medullary parts of MCP, ribs and pelvis)

Osteoclastoma or Brown Tumors (esp. at trabecular portions of jaw, long bones and ribs)

Pathological fractures

Skull ‘salt and pepper’ appearance

25
Investigations for asymptomatic primary hyperparathyroidism
Biochemistry: * Calcium, Phosphate, ALP * Urea. Creatinine, eGFR (treatment guidance) * 25 hydroxyvitamin D (for deficiency) * PTH by immunoassay Bone: * DXA scan for BMD (at distal radius, hip or lumbar spine) for osteoporosis * Vertebral spine assessment by X-ray or Vertebral fracture assessment by DXA Urine: 24h urine calcium and creatinine Abdominal: Urinary stones by KUB, USG, CT Optional: Bone turnover markers, TBS score by DXA, High-res peripheral quantitative CT
26
Indications for surgery in asymptomatic Primary hyperparathyroidism
Age under 50 Serum calcium \>0.25 mmol/L DXA T-score \< -2.5 at lumbar spine, total hip, femoral neck or distal radius Renal: * Creatinine clearance \<60cc/ min * 24h urine calcium \> 400mg/day * Presence of nephrolithiasis or nephrocalcinosis by imaging
27
Monitoring asymptomatic primary hyperparathyroidism without surgery
Annual serum calcium measurement DXA scan ever 1-2 years at 3 sites X-ray of VFA spine if indicated Renal: Annual eGFR, serum creatinine Renal stone suspected: 24h biochemical stone profile, renal imaging
28
Pre-operative localization of primary hyperparathyroidism
Surgical planning by imaging: * Parathyroid ultrasound (pre-op or intra-op) * Nuclear scintigraphy (Tc-99m Sestamibi scan)/ SPECT * CT with contrast - 4DCT scan * MRI
29
MoA of Tc-99m of parathyroid glands
Tc-99m taken up by mitochondria-rich oxyphil cells in parathyroid gland Planar images obtained shortly after injection and again at 2 hours to find foci of retained radio tracer activity
30
List all surgical options for primary hyperparathyroidism
Minimal invasive approach Multi-glandular disease: * Subtotal parathyroidectomy - resect 3.5 glands and preserve 50-80mg vascularized gland * Total thyroidectomy - with autotransplantation to forearm or cryopreservation for later transplant
31
Intra-operative monitoring technique during parathyroid surgery
PTH half-life - 4 minutes in pt with normal renal function Drop in serum PTH: 5-10mins Miami Criterion - 50% fall in PTH compared to highest of either pre-manipulation or pre-excision sample *Serum calcium takes 1-2 days to fall so NOT USED for intra-op monitoring*
32
Advantages and pre-requisites of Minimally invasive parathyroid surgery
Advantages: * Improve cosmesis * Short hospital stay * Decrease wound pain * Reduce morbidity * Decrease overall cost Pre-requisites * Pre-operative or intra-operative localization * Intra-operative PTH assay monitoring
33
Cause of secondary and tertiary hyperparathyroidism
Secondary: Physiological response to hypocalcemic state \> increase PTH secretion Tertiary: Prolonged secondary hyperparathyroidism \> Parathyroid hyperplasia \> autonomous secretion of PTH
34
Medical treatment option of Primary hyperparathyroidism MoA Indication
**Calcimimetics**: mimic calcium by allosteric action on Calcium Sensing Receptor Indication: * Surgery not appropriate or contraindicated * Severe hypercalcemia unable to undergo parathyroidectomy * Only normalize serum Ca, no effect on BMD + regular monitoring of annual serum Ca, DXA of 3 sites and Xray spine + eGFR and Creatinine + biochemical stone profile and imaging if needed
35
Tumors most linked with hypercalcemia
Lung (Squamous cell) Breast head and neck (Squamous) Kidney Myeloma Lymphoma
36
Mechanisms of hypercalcemia of malignancy
1. PTH-related peptide - **PTHrP** secretion 2. **Bone metastases** with direct local destruction or induction of local osteolysis by tumor cells 3. **Lymphokine production that activate osteoclasts** by hematological cancer (e.g. Multiple Myeloma) 4. Extra-renal production of 1,25 dihydroxy-vitamin D (e.g. Adult T-cell lymphoma)
37
Hypocalcemia * Cut-off
Serum Ca under 1.9mmol/L
38
S/S of hypocalcaemia
hypoCa leads to generalized hyperexcitability, symptomatic when [Ca] \<2mmol/L Sequence: sensory symptoms → latent tetany → gross spasm → laryngospasm → arrhythmia CATS - Convulsion, Arrhythmia, Tetany, Seizures and sensory changes □ Sensory changes: paraesthesia, perioral numbness □ Tetany: muscle spasms, convulsions, stridor (laryngeal spasm) → Carpopedal spasm: hand and feet spasms with hand adopting characteristic ‘main d’accoucheur’ appearance71 → Chvostek’s sign: tapping CN VII branches triggers facial twitching → Trousseau’s sign: inflation of BP cuff \>sysBP triggers carpal spasm within 3min □ Seizures: generalized tonic-clonic, absence, focal □ Heart: long QT, T wave inversion, arrhythmias (eg. TdP)
39
Investigations for PTH-independent hyperCa
screen for occult malignancy should be done: □ CXR for CA lung □ Serum/urine protein electrophoresis for multiple myeloma □ Mammogram □ CT abdomen, thorax
40
Management of hypercalcaemia of malignancy
Management: □ Acute Tx for severe hyperCa → IV saline, bisphosphonate ± calcitonin □ Novel agents MAb vs RANKL, eg. denosumab Recombinant OPG □ Monitor underlying tumour status ± modification of Tx (frequently a sign of tumour progression
41
S/S of chronic hypoCa
□ Chronic effects: → Neurological: basal ganglion calcification, generalized epilepsy, psychosis → Musculoskeletal: rickets, osteomalacia, dental hypoplasia → Dermatological: alopecia, brittle nails, dry skin → Others: cataract
42
HypoCa causes
43
Management of HypoCa
look for causes and treat accordingly! Severe or symptomatic: Ca \< 1.9 → IV 10% Ca gluconate infusion → Close monitoring of serum Ca →ECG and cardiac monitoring Mild: Ca \> 1.9 First-line: Oral Ca replacement - Caltrate, Oscal, Calcium gluconate Second-line: add vitamin D Third-line: 1,25-(OH)2-D3 added
44
Explain why most chronic renal failure presents with hypoCa
Mechanism: → ↓renal Ca reabsorption → ↓renal vitamin D3 formation → PO4 retention → ↑bound Ca + metastatic calcification → Uraemia → poor appetite → ↓GI/oral intake → Uraemia → bone resistance to PTH
45
Typical serum Ca level under HypoMg
classically a/w hypoK + hypoCa refractory to replacement □ Mechanism: ↓PTH action and secretion □ Mx: IV MgSO4 if severe, Mylanta / Mg tri if mild
46
Pseudohypoparathyroidism * Cause * S/S * Dx
PseudohypoPTH (PHP): □ Cause: maternal GNAS1 mutation (encoding for Gsα gene important for PTHr) ``` □ S/S: typically presents with Biochemical hypoPTH (↓Ca, ↑PO4) with ↑PTH and parathyroid hyperplasia Albright hereditary osteodystrophy (AHO) with mental retardation, short stature and shortened 4th and 5th metacarpals ``` □ Diagnosis: genetic testing
47
Causes of Vitamin D failure
failure: a/w a biochemical picture of ↓Ca ↓PO4 □ Causes: ↓intake: malnutrition, malabsorption ↓metabolism: ↓di-hydroxylation (liver disease), ↓hydroxylation (renal disease) ↓response: type II vitamin D-dependent rickets, type I vitamin D-dependent rickets ↑clearance of calcitriol: nephrotic syndrome, drugs (Dilantin, alcohol, glutethimide)
48
Investigation for Vitamin D failure
25-(OH)-D3 reflects level of intake and production - Low → nutritional insufficiency 1,25-(OH)2-D3 reflects level of active hormone - High/normal → type II vitamin D-dependent rickets (VDDR) Cause: vitamin D receptor defect, NOT amenable to calcitriol replacement - Low → type I vitamin D-dependent rickets (VDDR) Cause: 1α-hydroxylase deficiency, amenable to calcitriol replacement